ArticleActa pharmaceutica Sinica. B2019
Glycyrrhetinic acid binds to the conserved P-loop region and interferes with the interaction of RAS-effector proteins.
Article in Acta pharmaceutica Sinica. B, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 24 citations in OpenAlex.
- Advances in Understanding Renin-Angiotensin System-Mediated Anti-Tumor Activity of Natural Polyphenols.Biomolecules · 2025Review
- Complex Inhibitory Activity of Pentacyclic Triterpenoids against Cutaneous Melanoma In Vitro and In Vivo: A Literature Review and Reconstruction of Their Melanoma-Related Protein Interactome.ACS pharmacology & translational science · 2024Review
- Interpreting the efficacy enhancement mechanism of Chinese medicine processing from a biopharmaceutic perspective.Chinese medicine · 2024Review
- Mediating kinase activity in Ras-mutant cancer: potential for an individualised approach?Frontiers in pharmacology · 2024Review
- Semilicoisoflavone B Induces Apoptosis of Oral Cancer Cells by Inducing ROS Production and Downregulating MAPK and Ras/Raf/MEK Signaling.International journal of molecular sciences · 2023Article
- Okicamelliaside targets the N-terminal chaperone pocket of HSP90 disrupts the chaperone protein interaction of HSP90-CDC37 and exerts antitumor activity.Acta pharmacologica Sinica · 2022Article
- Identification of a novel PHGDH covalent inhibitor by chemical proteomics and phenotypic profiling.Acta pharmaceutica Sinica. B · 2022Article
- Atractylenolide-I covalently binds to CYP11B2, selectively inhibits aldosterone synthesis, and improves hyperaldosteronism.Acta pharmaceutica Sinica. B · 2022Article
- Mechanism of allosteric activation of SIRT6 revealed by the action of rationally designed activators.Acta pharmaceutica Sinica. B · 2021Article
- Deubiquitinase USP35 modulates ferroptosis in lung cancer via targeting ferroportin.Clinical and translational medicine · 2021Article
- Discovery of the anti-angiogenesis effect of eltrombopag in breast cancer through targeting of HuR protein.Acta pharmaceutica Sinica. B · 2020Article
- 20(Acta pharmaceutica Sinica. B · 2020Article
- Esculetin Inhibits Cancer Cell Glycolysis by Binding Tumor PGK2, GPD2, and GPI.Frontiers in pharmacology · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Members of the
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.